The Trendlines Group (Trendlines) (SGX:42T
) announced that its portfolio company Seger Surgical Solutions Ltd (Seger) achieved the successful completion of three first-in-human cases in a clinical trial for its proprietary SEGER IDEA laparoscopic bowel closure device.
The above procedures were conducted at Zacamil National Hospital in El Salvador.
Trendlines says that the SEGER IDEA device enables surgeons to align, close, and staple the common enterotomy quickly and securely entirely inside the body, eliminating the need for complex hand-sewn suturing or the traditional "extracorporeal" method, which requires larger incisions and lifting the bowel outside the abdominal cavity.
Trendlines add that the El Salvador trial was designed to demonstrate the safety and efficacy of this approach.
Apart from the three successful cases, some of the key clinical highlights include reduced procedure time and enhanced patient recovery.
“The success of our first-in-human cases in El Salvador validates our vision for the future of surgery," says Seger's CEO, Shahar Millis.
“This milestone surgery highlights the quality and potential of companies within the Trendlines portfolio,” says Haim Brosh, Trendlines’ CEO.
Shares in Trendlines closed 0.4 cent lower, or 7.02% down at 5.3 cents on March 17.
